IMPORTANCE Human genetic studies have indicated that plasma lipoprotein(a) (Lp[a]) is causally associated with the risk of coronary heart disease (CHD), but randomized trials of several therapies that reduce Lp(a) levels by 25% to 35% have not provided any evidence that lowering Lp(a) level reduces CHD risk.
A polipoprotein(a), which is encoded by the LPA gene, covalently binds to a cholesterol-rich low-density lipoprotein (LDL) particle to form lipoprotein(a) (Lp[a]). 1 Meta-analyses of prospective observational studies have reported that higher plasma Lp(a) concentration is associated with dose-dependent higher risk of coronary heart disease (CHD). 2 Furthermore, mendelian randomization analyses have provided strong evidence that the association between Lp(a) and risk of CHD is likely to be causal. [3] [4] [5] However, several large randomized trials evaluating therapies that lower Lp(a) concentration by between 20% and 35% (including niacin, cholesterol ester transfer protein inhibitors, and PCSK9 inhibitors) have not provided clear evidence that lowering plasma Lp(a) concentration reduces the risk of cardiovascular events beyond that which would be expected from the observed LDLlowering effect of these therapies. [6] [7] [8] [9] [10] [11] Although these trials were not specifically designed to assess the Lp(a)-lowering effect of these agents, these trials raise the question of how much Lp(a) concentration must be lowered to produce a clinically meaningful reduction in cardiovascular events. Therapies that more specifically and potently lower Lp(a) concentrations by up to 90% by inhibiting apolipoprotein(a) synthesis are in development. 12 Whether lowering Lp(a) concentrations with these new therapies will reduce the risk of cardiovascular events is unknown.
Owing to the skewed distribution of plasma Lp(a) concentration, prior studies have reported the association between log-transformed concentrations of Lp(a) and CHD risk. 2, [13] [14] [15] Changes in log-transformed Lp(a) concentrations represent proportional changes in Lp(a) concentrations. However, proportional reduction is not a useful metric for assessing the potential clinical benefit of lowering Lp(a) level because concentrations can vary by as much as 1000-fold among members of the same population, and therefore, the same proportional change in Lp(a) concentration can result in markedly different absolute changes, depending on the initial Lp(a) concentration. 16 Importantly, statins and other therapies that reduce LDL particle concentrations are associated with a dosedependent reduction in the risk of cardiovascular events that is determined by the absolute (rather than the proportional) change in LDL cholesterol (LDL-C) level. [17] [18] [19] Because Lp(a) contains an LDL particle, we hypothesized that there would be evidence to support a clinical association of Lp(a) with the risk of CHD that may also be proportional to the absolute change in circulating Lp(a) mass concentration. To test this hypothesis, we created a genetic score to estimate the magnitude and shape of the relationship of Lp(a) with the risk of CHD. We then estimated the absolute change in plasma Lp(a) concentration required to achieve the equivalent change in CHD risk as a 38.67-mg/dL (ie, 1-mmol/L) change in LDL-C level (to convert to millimoles per liter, multiply by 0.0259), a change in LDL-C that has been demonstrated to produce a clinically meaningful 20% to 25% reduction in the risk of cardiovascular events in short-term trials. [17] [18] [19] Our objective was to make inferences about how much Lp(a) concentration must be reduced pharmacologically to produce a clinically meaningful reduction in CHD risk and thereby determine who is most likely to benefit from treatment with Lp(a)-lowering therapy to inform clinical guidelines and the design of randomized trials evaluating Lp(a)-lowering therapies.
Methods

Study Population and Outcomes
We studied 48 333 participants of European descent (including 20 793 with CHD) from 5 studies for whom individual participant-level data were available as part of the CHD Exome+ Consortium. Descriptions of the included studies are provided in eMethods 1 of the Supplement. The primary outcome was CHD, defined as CHD death, nonfatal myocardial infarction, or (for 3 of the studies) other coronary events with International Statistical Classification of Diseases and Related Health Problems, Tenth Revision codes I20-25. Participants provided written informed consent for genetic studies. As this was an analysis of anonymized data that had already been collected, ethical approval was not sought for this particular investigation.
LPA Genetic Score
All CHD Exome+ Consortium participants were genotyped using a customized version of the Illumina Exome Beadchip array, which included ultrafine mapping of the LPA gene region involving 2426 variants genotyped within a 660-kb window (eFigure 1 in the Supplement). To select variants for inclusion in the genetic score, we identified variants in the LPA gene region that were conditionally associated with Lp(a) concentrations at a genome-wide level of significance (P <5×10 −8 ) using forward stepwise regression among participants free from CHD at baseline in each study. We adjusted for study, age, sex, and 5 principal components of ancestry. Genetic variants correlated with a selected variant at r 2 greater than 0.4 were excluded from further steps of the procedure (eFigure 2 in the Supplement). For each participant, we calculated a weighted genetic score by summing the number of Lp(a)-raising alleles inherited at each variant included in the score, weighted by each variant's association with absolute change in Lp(a) mass
Key Points
Question How much does plasma lipoprotein(a) need to be lowered to produce a clinically meaningful reduction in the risk of coronary heart disease?
Findings In a mendelian randomization analysis involving more than 80 000 patients and more than 150 000 controls, coronary heart disease risk was proportionally associated with the absolute change in plasma lipoprotein(a) mass concentration; a 101.5-mg/dL change in lipoprotein(a) concentration was associated with the same coronary heart disease risk as a 38.67-mg/dL (ie, 1-mmol/L) change in low-density lipoprotein cholesterol level.
Meaning Lipoprotein(a) concentration must be lowered by approximately 100 mg/dL to achieve the same reduction in coronary heart disease risk as can be achieved by lowering low-density lipoprotein cholesterol level by 38.67 mg/dL.
concentration (measured in milligrams per deciliter). In sensitivity analyses, we repeated the primary analyses using different choices of variants in the genetic scores, as described in eMethods 2 in the Supplement.
Study Design
To assess the dose-response shape of the association between genetically predicted Lp(a) and CHD risk, we divided participants into deciles of the genetic score and measured the association between each decile of genetically predicted Lp(a) concentration and the risk of CHD using the first decile as the reference group. Informed by the shape of the association, we estimated the association between the LPA score and the risk of CHD for absolute changes in Lp(a) concentration.
To estimate the absolute reduction in Lp(a) concentration required to have the same change in CHD risk as a 38.67-mg/dL decrease in LDL-C level, we used the following protocol (eFigure 3 in the Supplement). First, we measured the association between the LPA score and the risk of CHD per 10-mg/dL decrease in genetically predicted Lp(a) concentration. Next, we measured the association between a genetic score consisting of variants in or near genes that encode the targets of currently available LDL-C-lowering therapies and CHD risk per 10-mg/dL decrease in genetically predicted LDL-C (eTable 1intheSupplement). 20 We then calculated the ratio between these 2 estimates to obtain the change in Lp(a) concentration that has an equivalent association with CHD risk as a 1-mg/dL change in LDL-C level. To estimate the amount Lp(a) concentration must be reduced to have the same association with CHD risk as a 38.67-mg/dL reduction in LDL-C level, we multiplied this ratio by 38.67. Finally, we estimated the predicted shortterm change associated with different magnitudes of pharmacological lowering of Lp(a) concentration by converting the change in Lp(a) concentration into a change in LDL-C level having an equivalent predicted effect on CHD risk and using the estimated change associated with statin treatment per 38.67-mg/dL reduction in LDL-C level, as reported by the Cholesterol Treatment Trialists' Collaboration.
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Statistical Analyses
We estimated the association of each variant with Lp(a) or LDL-C concentration using linear regression and with CHD risk using logistic regression. All regression analyses were performed separately in each of the studies, adjusting for age, sex, and the first 5 principal components of ancestry; these estimates were combined across studies in a fixed-effects inverse variance-weighted meta-analysis. Heterogeneity was assessed using the I 2 statistic. Mendelian randomization estimates were then obtained from these variant-specific estimates using a previously reported method that accounts for correlation between variants. 21 Nonlinearity in the mendelian randomization estimates of the shape of the association of Lp(a) change with the risk of CHD was assessed using fractional polynomials, as described elsewhere. 22 For external replication in an independent sample, we performed the same analyses using summarized genetic associations with CHD risk from the Coronary Artery Disease Genome Wide Replication and Meta-analysis (CARDIOGRAM) plus The Coronary Artery Disease (C4D) Genetics (CARDIOGRAMplusC4D) consortium in up to 62 240 patients and 127 299 controls.
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All analyses were performed using the statistical software platform R version 3.4.1 (R Programming). A detailed description of the methods is provided in eMethods 2 of the Supplement.
Results
Participant Characteristics
The baseline characteristics of participants are presented in Table 1 . Across the 5 studies contributing to the initial sample, the median Lp(a) concentration varied from 13.6 mg/dL to 43.3 mg/dL (eTable 2 and eFigure 4 in the Supplement).
LPA Genetic Score
The stepwise selection procedure identified 43 genetic variants conditionally associated with Lp(a) (eTable 3 in the Supplement). The genetic score comprising these variants explained 51% to 63% of the variance in Lp(a) concentration in each study (eFigure 5 in the Supplement). This explanatory ability is lower than observed previously 24 because our genetic score was constructed conservatively to minimize bias owing to overfitting. Associations of each variant with Lp(a) concentration and CHD risk are displayed in Figure 1 .
Association of LPA Genetic Score With CHD
In analyses dividing the population into deciles of genetically predicted absolute Lp(a) mass concentration, the expo- sure-outcome association for log-transformed CHD risk was approximately linear, ie, fixed changes in absolute Lp(a) concentrations led to equal odds ratios (ORs) for CHD regardless of the starting Lp(a) concentration ( Figure 2A ). By contrast, the exposure-outcome association for deciles of log-transformed Lp(a) concentration was curvilinear ( Figure 2B ), with fixed proportional changes in Lp(a) concentrations leading to greater log-ORs for individuals with higher baseline Lp(a) concentrations (and hence, increasingly greater absolute changes in Lp[a] concentrations). These findings are consistent and support the hypothesis that the risk of CHD is log-linearly proportional to absolute changes in Lp(a) concentration. Overall, each 10-mg/dL lower genetically predicted Lp(a) level was associated with a 5.8% lower risk of CHD (OR, 0.942; 95% CI, 0.933-0.951; P =3×10 −37
). There was no evidence of heterogeneity with similar genetic association estimates obtained across all studies independent of the type of Lp(a) assay used (eFigures 6 and 7 in the Supplement). Estimates were also similar in sensitivity analyses that varied the number of genetic variants included in the LPA score (eTable 4 in the Supplement). In external replication analyses involving participants from CARDIOGRAMplusC4D, a 10-mg/dL lower genetically predicted Lp(a) level was associated with a 5.2% lower risk of CHD (OR, 0.948; 95% CI, 0.941-0.955; P =1×10 −47 ).
Expected Clinical Benefit of Lowering Lp(a) Concentration
Using the LDL-C genetic score, a 10-mg/dL genetically predicted lower LDL-C level was associated with a 14.5% lower risk of CHD (OR, 0.855; 95% CI, 0.818-0.893; P =2×10 Changes in genetically predicted Lp(a) and LDL-C concentrations represent lifelong exposure to these lipoproteins. Hence, to estimate the effect of lowering Lp(a) concentration in a short-term trial, we assumed that if lifelong exposure to 101.5-mg/dL lower Lp(a) concentration has the same association with CHD risk as lifelong exposure to 38.67-mg/dL lower LDL-C level, then short-term exposure to 101.5-mg/dL lower Lp(a) concentration should have the same association with CHD risk as short-term exposure to 38.67-mg/dL lower LDL-C levels observed in randomized trials. This assumption is valid only if changes in Lp(a) concentration and LDL-C level have similar cumulative associations with CHD over time. It is further supported by the observation that the ratio of the association of lifelong exposure to Lp(a) with CHD risk estimated from mendelian randomization to the association of intermediateterm exposure to Lp(a), estimated from observational studies in the Emerging Risk Factors Consortium, 2 is very similar to the ratio of the association of lifelong exposure to LDL-C with CHD risk estimated from mendelian randomization to the association of intermediate-term exposure to LDL-C in the Emerging Risk Factors Consortium ( Figure 3 ; eFigure 9 in the Supplement). 25 Therefore, Lp(a) and LDL-C appear to have similar cumulative associations with the risk of CHD over time. Table 2 shows the expected clinical benefit in CHD risk from both lifelong and short-term exposure to absolute differences in Lp(a) concentration. Lifelong estimates are conventional mendelian randomization estimates, while short-term estimates are calculated using the difference in Lp(a) concentration needed to achieve the same change for a given reduction in LDL-C level over a median of 5 years of treatment with a statin, as reported by the Cholesterol Treatment Trialists' Collaboration.
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Independent Association of Lp(a) and LDL-C-Lowering Therapies
To assess whether the association of lowering Lp(a) concentration with the risk of CHD is likely to be independent of lowering LDL-C level with statins, we divided the population into 3 groups based on the number of LDL-C-lowering alleles each participant inherited at a common variant (rs12916)i nt h e 3-hydroxy-3-methyl-glutaryl-CoA reductase (HMGCR) gene, which encodes the target of statins. 
Discussion
We found that the association of genetically predicted plasma Lp(a) with the risk of CHD was linearly proportional to the absolute difference in Lp(a) concentration. Absolute differences in Lp(a) concentration of approximately 100 mg/dL had an equivalent association with CHD risk as a 38.67-mg/dL difference in LDL-C level. The results of this study may have important implications for informing clinical practice guidelines on the use of Lp(a)-lowering therapies, for designing randomized trials to evaluate Lp(a)-lowering therapies currently in development, and for designing screening programs to reduce the global burden of CHD. Because a 100-mg/dL difference in Lp(a) concentration had the same association with CHD risk as a 38.67-mg/dL difference in LDL-C level, the results of this study suggest that pharmacologically lowering Lp(a) concentration by approximately 100 mg/dL should reduce the risk of CHD (CHD death or nonfatal myocardial infarction) by approximately 22% to 25% in a 3-to 5-year randomized trial, similar to the associa- tion that has been observed for a 38.67-mg/dL reduction in LDL-C level during treatment with a statin. [17] [18] [19] Therefore, it follows that lowering Lp(a) concentration by 80 mg/dL might be expected to reduce the risk of CHD events by approximately 18% to 20%, while lowering Lp(a) concentration by 50 mg/dL might reduce CHD events by 10% to 12% (Table 2) , assuming that there are no unrecognized competing risks associated with lowering Lp(a) concentration. Therefore, only persons with very high Lp(a) concentrations are likely to benefit substantially from therapies that reduce Lp(a) concentration.
This finding likely explains why therapies that reduce Lp(a) concentration by 20% to 35% have failed to provide clear evidence that lowering Lp(a) concentration reduces the risk of cardiovascular events in previous randomized trials even though Lp(a) is a genetically supported target. The median Lp(a) concentration among participants enrolled in these trials was approximately 12 to 20 mg/dL. [7] [8] [9] [10] [11] Therefore, a 30% reduction in Lp(a) concentration would translate into only a 3-to 6-mg/dL absolute reduction in circulating plasma Lp(a) concentration, a small absolute reduction that was likely far too mod- est to reduce the risk of cardiovascular events appreciably in a short-term randomized trial. The results of this study suggest that randomized trials evaluating new, more potent Lp(a)-lowering therapies in development should be designed to enroll individuals with very high baseline Lp(a) concentrations of 90 to 100 mg/dL or more. Reducing Lp(a) concentration by 80% to 90% in such individuals should translate into large absolute reductions in Lp(a) concentrations of 70 to 90 mg/dL, which should in turn translate into approximately a 15% to 20% proportional reduction in the risk of CHD events. Enrolling patients at high risk of CHD owing to markedly elevated Lp(a) concentration in the initial proof-of-concept clinical trials is similar to the strategy used by the Scandinavian Simvastatin Survival Study trial, 28 which enrolled high-risk patients with markedly elevated LDL-C concentrations and was the first trial to demonstrate that treatment with statins led to large, clinically meaningful reductions in the risk of cardiovascular events. The magnitude of the pharmacologic reduction in Lp(a) mass that is likely needed to produce clinically meaningful reductions in CHD risk estimated in this study is larger than estimated in a 2018 study evaluating changes in Lp(a) during treatment with niacin. 29 However, whereas that previous study involved informal estimates of the reversible CHD risk by lowering Lp(a) concentrations in a short-term trial, 29 we used a more systematic approach. In particular, our study estimated the differences in genetically predicted Lp(a) and LDL-C concentrations needed to have the same change in lifetime CHD risk and incorporated an assessment of the differential cumulative associations of Lp(a) and LDL-C with CHD risk over time to estimate how much Lp(a) concentration must be lowered pharmacologically to produce the same change as lowering LDL-C level by 38.67 mg/dL (ie, 1 mmol/L) with a statin. This approach has been successfully used to accurately anticipate the results of several recent trials. 26,27,30 Similar analyses to those used in the current study are needed before it would be possible to accurately anticipate the potential effect of pharmacologically lowering Lp(a) on the risk of stroke, peripheral vascular disease, aortic stenosis, or composite end points that include these outcomes. 31 Finally, it should be noted that plasma Lp(a) concentration is largely heritable. Therefore, if the linear relationship with CHD risk continues at very high absolute Lp(a) concentrations (as occurs for LDL-C), then Lp(a) concentrations in excess of 200 mg/dL may be associated with a 3-to 4-fold increased lifetime risk of CHD (OR, 3.30; 95% CI, 2.75-3.96) and thus may represent an inherited lipoprotein disorder that is associated with a similar lifetime risk of CHD as heterozygous familial hypercholesterolemia but with a prevalence that may be 2-fold higher than that of heterozygous familial hypercholesterolemia.
32,33 Therefore, screening for individuals with extremely elevated Lp(a) concentrations and treating them with one of the new Lp(a)-lowering therapies in development could potentially have the same effect on reducing the global burden of CHD as current screening programs designed to detect and treat individuals with familial hypercholesterolemia.
Limitations
Our study has limitations. Multiple different assays were used to measure Lp(a) concentrations in the included studies. However, we focused only on absolute differences in Lp(a) associated with genetic variants, which were very similar across all included studies, regardless of assay used or baseline Lp(a) concentrations. In addition, our estimate of the effect of lowering Lp(a) is agnostic to the mechanism of action, and hence our use of plasma Lp(a) mass concentration to estimate the doseresponse relationship does not imply that our estimates are solely via changes in plasma Lp(a) mass concentration. If pharmacologic Lp(a) lowering has associations not adequately captured by the genetic variants (eg, antithrombotic associations), then smaller absolute reductions in Lp(a) than estimated here may produce clinically meaningful reductions in CHD risk.
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Conclusions
The association of genetically predicted Lp(a) with CHD risk was linearly proportional to the absolute change in Lp(a) mass concentration. Large absolute reductions in Lp(a) concentration of approximately 100 mg/dL are likely necessary to achieve clinically meaningful reductions in the risk of CHD similar in magnitude to what can be achieved by lowering LDL-C level by 38.67 mg/dL (ie, 1 mmol/L) with a statin. An overarching aim of precision medicine is to direct the right treatment to the right person at the right dose at the right time.
Recently, mendelian randomization (MR) studies have contributed to our evidence base for precision medicine by harnessing genetic information to assess whether associations of exposures with cardiovascular outcomes may be causal. The ascendance of MR studies takes advantage of the explosive growth of genomewide genetic data in multiple cohorts collaborating within global meta-analyses. In MR studies, genetic variants associated with an exposure of interest serve as unconfounded proxies for altered levels of the exposure. This supplementary material has been provided by the authors to give readers additional information about their work. Data were obtained from a questionnaire, a physical examination, and blood samples including deoxyribonucleic acid extraction. The case definition was fatal and non fatal myocardial infarction and other coronary events according to ICD10 codes I20 I25. Control participants are members of the CCHS cohort who were free from coronary disease at baseline and after follow up.
An immunoturbidimetric assay (either supplied by DiaSys or Technicon Axon) was used to measure Lp(a) in CCHS. All analyses in CCHS were additionally adjusted for Lp(a) assay supplier.
Copenhagen General Population Study (CGPS)
The CGPS is a population based prospective study initiated in 2003 with ongoing enrollment. Participants were selected on the basis of the national Danish Civil Registration System to reflect the adult Danish population age 20 to 100 years. Data were obtained from a questionnaire, a physical examination, and blood samples including deoxyribonucleic acid extraction. An immunoturbidimetric assay (either supplied by DiaSys or Denka Seiken) was used to measure Lp(a) in CGPS. All analyses in CGPS were additionally adjusted for Lp(a) assay supplier.
The Copenhagen Ischaemic Heart Disease Study (CIHDS)
CIHDS is a study comprising of 6,625 cases (4,635 men and 1,990 women) with myocardial infarction and other major acute coronary syndromes (ICD10 codes I20 to I25) and 10,368 age and sex matched controls from CGPS. Blood samples including DNA extraction were available. The cases were recruited between 1991 and 2009 from the Copenhagen University Hospital. In addition to a diagnosis of coronary heart disease, these cases also had stenosis or atherosclerosis on coronary angiography and/or positive results on exercise electrocardiography. For estimating associations with coronary heart disease, CGPS and CIHDS are treated together as a single case control study. Lp(a) measurements from CIHDS were not including in this project.
Individuals in the CCHS 2001-2003 examination and the first 5592 individuals in the CGPS had lipoprotein(a) measured immediately after sampling using an assay from DiaSys (Diagnostic Systems), whereas subsequent individuals in the CGPS had lipoprotein(a) measurements done using an assay from Denka Seiken; of the latter, 12,577 were stored at 80 °C until measurement, whereas the remaining 31,211 were measured on fresh samples.
European Prospective Investigation into Cancer and Nutrition Cardiovascular Disease Study (EPIC CVD)
EPIC is a multi centre prospective cohort study of 519,978 participants (366,521 women and 153,457 men, mostly aged 35-70 years) recruited between 1992 and 2000 in 23 centres located in 10 European countries. Participants were invited mainly from population based registers (Denmark, Germany, certain Italian centres, the Netherlands, Norway, Sweden, UK). Other sampling frameworks included: blood donors (Spain, and Turin and Ragusa in Italy); screening clinic attendees (Florence in Italy and Utrecht in the Netherlands); people in health insurance programmes (France); and health conscious individuals (Oxford, UK). About 97% of the participants were of white European ancestry. EPIC CVD is a nested case cohort design comprising all cardiovascular disease (CVD) cases from the large EPIC cohort and a random sample of the entire cohort ("subcohort"). The case definition was fatal and non fatal myocardial infarction and other coronary events according to ICD10 codes I20 I25.
A particle enhanced immunoturbidimetric assay on a Roche MODULAR ANALYTICS EVO analyser was used to measure Lp(a) in EPIC CVD. Details of blood draw and storage procedures in each of the EPIC centres can be found in the consortium protocol paper (1).
Prospective Study of Pravastatin in the Elderly at Risk trial (PROSPER)
PROSPER was a controlled, randomised study involving 2,804 men and 3,000 women aged 70 82, with a history of, or risk factors for cardiovascular disease. Participants were randomised to either 40mg pravastatin per day or matching placebo. The case definition was fatal coronary heart disease or nonfatal myocardial infarction.
Lp(a) was not measured in PROSPER. This study was only used in testing the association of the Lp(a) genetic risk score with CHD.
West of Scotland Coronary Prevention Study (WOSCOPS)
WOSCOPS was a primary prevention clinical trial of 6,595 men in the West of Scotland district aged 45 to 64 years with elevated cholesterol levels (moderate hypercholesterolemia). Between 1989 and 1991, 6,595 men who had no evidence of previous myocardial infarction were randomised to either receive pravastatin (40 mg once daily) or placebo. To be eligible for enrolment, participants had to have two measurements of LDL C >155mg/dL, with at least one measurement >174mg/dL. A nested case control design was used for this study, selecting as cases individuals who self reported a history of coronary disease at baseline or who had a coronary event during follow up. Controls were participants who were free of cardiovascular disease at baseline and at the end of follow up, frequency matched to the cases for sex and age (in 5 year bands). The case definition was fatal coronary heart disease or nonfatal myocardial infarction.
An ELISA assay (supplied by Innogenetics) was used to measure Lp(a) in WOSCOPS on fasted samples (8 hours+) of blood plasma that had been stored at 70 °C for 1 to 5 years.
Details on the numbers and percentage of participants with Lp(a) levels above various threshold values are provided in Supplementary Table S2 . A violin plot of the distribution of Lp(a) in each study is presented as Supplementary Figure S4 . Lp(a) assays are not uniformly calibrated (2) and large differences in measurements using different assays have been demonstrated previously (3).
eMethods 2. Detailed statistical methods
LPA GENETIC SCORE
To select variants for inclusion in the LPA genetic score, we started with the full list of 2462 candidate variants in the LPA gene region (660kb window). 936 variants remained available for analysis after filtering out variants that: were monomorphic across all samples, severely deviated from Hardy-Weinberg equilibrium ( < 1 × 10 6 for variants with MAF 0.05 and < 1 × 10 15 for variants with MAF < 0.05), or did not have a call rate > 95% in each study. Values of Lp(a) above 130 mg/dL were taken to be 130 mg/dL (winsorization) to reduce the effect of extreme outliers on the analyses. In total, 5% of Lp(a) measurements were above this threshold.
At each step of the selection algorithm, we tested the association of each variant in a linear model where the dependent variable was Lp(a) and independent variables were age, sex, study cohort, assay method, 5 principal components of ancestry, and all variants selected in a previous step of the algorithm. The variant that was associated with Lp(a) in this conditional analysis with the lowest p value below a threshold of 5 × 10 8 was added to the set of selected variants. Once a variant was included in the analysis, any other variant that was correlated with the selected variant at r 2 > 0.4
was removed from the set of candidate variants. We then continued to the next step until all variants were either selected, removed due to linkage disequilibrium with a selected variant, or were not strongly associated ( < 5 × 10 8 ) with Lp(a) in the conditional analysis. A weighted genetic score was then constructed with weights being the conditional associations of each variant with Lp(a) (conditional on all the other variants in the score). The variants and their associations (marginal and conditional) with the risk factor and outcome are provided in Supplementary Table S3 . Marginal associations of the variants with Lp(a) in each study are displayed in Supplementary Figure S6 . Despite substantial differences between the mean and median concentrations of Lp(a) in each study, the genetic associations are similar across studies, suggesting that the assay type affects the baseline concentration of Lp(a), but not changes in Lp(a). As we adjust for study (and assay type if appropriate) in all analyses, differences in baseline concentrations of Lp(a) will not influence the analysis -only genetic associations with Lp(a) are used in our calculations.
The variant selection strategy was chosen with the aim of maximizing the proportion of variance in Lp(a) explained subject to certain constraints. Mendelian randomization estimates with highly correlated genetic variants can be unstable, as the genetic correlation matrix is inverted as part of the analysis. Therefore we set a correlation threshold of r 2 = 0.4 to ensure that no two selected variants had a pairwise squared correlation greater than 0.4. To minimize overprediction, we strictly avoided including too many variants in the score. Hence, each variant included in the model was required to be conditionally associated with Lp(a) at a genome wide level of significance ( < 5 × 10 8 ). The upshot of this is that less of the variance in Lp(a) is explained by the genetic score than perhaps could have been with a more liberal choice of variants; however, a sizeable proportion of variance in the risk factor is explained, and this choice of variants should lead to more robust inferences.
A regional association plot of the gene region indicating the 43 variants included in the LPA genetic score is provided as Supplementary Figure S1 , and a schematic diagram of how the LPA genetic score was constructed is provided in Supplementary Figure S2 . A plot showing the proportion of variance in Lp(a) explained by the genetic score in each study and at each step of the variant selection algorithm is provided as Supplementary Figure S5 .
SHAPE OF RELATIONSHIP BETWEEN LIPOPROTEIN(a) AND CORONARY HEART DISEASE RISK
The relationship between genetically predicted Lp(a) levels and CHD risk was assessed in two ways: (i) within deciles of genetically predicted Lp(a); and (ii) across the entire range of genetically predicted Lp(a) using fractional polynomials (4). These analyses are equivalent to a two stage Mendelian randomisation analysis, where the analysis in the second stage is not restricted to be linear, and the Lp(a) genetic risk score is used as the instrument variable. The deciles of Lp(a) were created by splitting the distribution of the genetic risk score of Lp(a) across all of the studies into deciles. As the genetic risk score only depends on the number of Lp(a) increasing variants, baseline Lp(a) level in each study should not affect the distribution of individuals in each of the decile groups. The associations of these deciles with risk of CHD were then assessed using logistic regression in each study separately, and meta analysed using multivariate random effects meta analysis. To reflect the amount of information within each group, 95% confidence intervals were estimated from variances attributed to each group, including the reference group, using floating absolute risks (5).
The best fitting fractional polynomial model (of either degree 1 or 2) was also used to flexibly assess the relationship between genetically predicted Lp(a) and CHD risk using logistic regression across studies (i.e. all cohorts are fitted in a single model). A test of linearity was performed using logistic regression across studies, by testing for a non zero quadratic term in a quadratic model. These analyses were adjusted age, sex, and the first five principal components of ancestry; the fractional polynomial and quadratic models were also adjusted for study. The mvshape R package (https://github.com/jrs95/mvshape) was used to perform these analyses.
Additionally, we estimated the relationship between log transformed Lp(a) and log odds of CHD, as has been considered in previous epidemiological investigations (6) . In contrast to the linear relationship between absolute levels of Lp(a) and log odds of CHD, the relationship between log transformed Lp(a) and log odds of CHD was curvilinear, with an increased association between genetically predicted log transformed Lp(a) and CHD risk at greater Lp(a) levels. The linear and curvilinear relationships are not in contradiction, but in fact are completely compatible: equal changes in log transformed Lp(a) correspond to greater changes in absolute concentrations of Lp(a) for greater baseline values (and therefore stronger associations with CHD risk).
For untransformed Lp(a), the test of linearity using a quadratic term was not rejected (p = 0.11). The best fitting fractional polynomial was the linear model. For log transformed Lp(a), the test of linearity using a quadratic term was rejected (p < 0.001). The best fitting fractional polynomial included quadratic and cubic terms.
CAUSAL EFFECT OF LIPOPROTEIN(a) ON RISK OF CORONARY HEART DISEASE
The Mendelian randomization effect of Lp(a) on CHD risk was calculated using summarized data on variants in the LPA genetic score. Genetic associations were derived in each study separately, and then meta analysed across studies. This analysis assumes a linear relationship between Lp(a) and the log odds of CHD risk. Genetic associations with Lp(a) were estimated using linear regression in participants not having a previous CHD event at baseline, adjusting for age, sex, and 5 principal components of ancestry (plus Lp(a) assay method if relevant). Genetic associations with CHD risk were estimated using logistic regression, with the same adjustment. A matrix of genetic correlations between variants was estimated in participants not having a previous CHD event at baseline only.
The summarized genetic association estimates were combined into Mendelian randomization estimates using weighted generalized linear regression accounting for the correlation between variants. If variants were uncorrelated, this method would be equivalent to combining the variant specific causal estimates in an inverse variance weighted meta analysis (or combining the variants into a single genetic score variable and calculating the Mendelian randomization ratio estimate using this score). The regression model was:
where is the Mendelian randomization causal estimate, is a vector of the genetic associations (beta coefficients) with the risk factor, is a vector of the genetic associations with the outcome, and the weighting matrix has terms , where is the standard error of the genetic association with the outcome for the jth variant, and is the correlation between the j 1 th and j 2 th variants. The causal estimate from this weighted generalized linear regression is , and the standard error is , where T is a matrix transpose, and is the maximum of the residual standard error from the regression model and 1. This is equivalent to assuming a multiplicative random effects model on the variant specific causal effect estimates. By fixing to be no lower than 1, we ensure that the random effects analysis is no more precise than a fixed effect analysis would be.
The reason for using summarized data in our analysis, even though we had individual level data available, is so that we could combine evidence first across studies, and then across genetic variants. This approach corresponds to where we would expect to see heterogeneity in our associations, and produces estimates that are less susceptible to weak instrument bias (7). This method has been described previously (8) and was implemented using the MendelianRandomization package in R (available for download at https://cran.r project.org/web/packages/MendelianRandomization/) (9) . When run as a fixed effect analysis, it is equivalent to the commonly used two stage least squares method that requires individual level data.
CAUSAL EFFECT OF LDL CHOLESTEROL ON RISK OF CORONARY HEART DISEASE
To assess the causal effect of LDL C on CHD risk, we used a combined LDL score comprising 8 genetic variants in separate gene regions each of which has been specifically linked with LDL C (it either encodes a biologically relevant compound to LDL C, or is a proxy for an existing or proposed LDL C lowering drug). These gene regions are: HMGCR (proxy for statin treatment), PCSK9 (proxy for PCSK9 inhibition), NPC1L1 (proxy for ezetimibe), APOB (encodes biologically relevant apolipoprotein B), ABCG5/G8 (bile acid sequestrant), SORT1 (antisense oligonucleotide RNA inhibitor targeting this pathway currently under development), APOE (encodes biologically relevant apolipoprotein E), and LDLR (encodes biologically relevant LDL receptor). The specific choice of variant in each gene region to include in the analysis was based on the lead variant from the Global Lipids Genetic Consortium's 2010 analysis. As these variants were discovered in an almost entirely non overlapping set of studies to the Exome+ consortium (the only overlap was up to 1772 EPIC CVD participants from the Norfolk centre), there should be minimal bias due to winner's curse in the Mendelian randomization estimate calculated in the Exome+ consortium.
Summarized genetic associations with LDL C were calculated in the same way as associations with Lp(a) described above, and Mendelian randomization estimates were calculated using these summarized estimates as described above.
Genetic associations with LDL C and with CHD risk for the 8 variants in the combined LDL score are provided in Supplementary Table S1 and displayed graphically in Supplementary Figure S5 . Each of the variants approximately lies on the same straight line through the origin, indicating that the Mendelian randomization estimates based on each individual variant are similar. In particular, the Mendelian randomization estimate is relatively insensitive to which of these variants are included in the combined LDL genetic score. The similarity of these estimates gives us reasonable confidence that the Mendelian randomization assumptions are satisfied for the LDL C score.
POTENTIAL CLINICAL BENEFIT OF LIPOPROTEIN(a) LOWERING THERAPIES
We here detail the approach for translating the Mendelian randomization estimate for the effect of This calculation is numerically equivalent to calculating the ratio between the estimates for the life long (genetically predicted) and short term (clinical trial) effect of LDL C on CHD risk, and dividing the genetically predicted effect of life long Lp(a) on CHD risk by this ratio to estimate the short term effect of Lp(a) on CHD risk.
A 95% confidence interval for this quantity was calculated by a Monte Carlo procedure. We took a random draw from a normal distribution with mean taken as the Mendelian randomization estimate for LDL C [log(0.855)] and standard deviation taken as the standard error of this estimate, divided by a random draw from a normal distribution with mean taken as the Mendelian randomization estimate for Lp(a) [log(0.942)] and standard deviation taken as the standard error of this estimate, and multiplied by 38.67. We repeated this procedure 100 000 times, and took the 2. This is a 5.8% reduction in CHD risk. The 95% confidence interval for this quantity is 4.9-6.7%, based on the standard error of the Mendelian randomization estimate. Confidence intervals for the predicted short term effect of Lp(a) are calculated using a bootstrap procedure as described above, except that we account for the uncertainty in three estimates (two Mendelian randomization estimates, and the effect of statins from clinical trials) by drawing from three normal distributions.
SENSITIVITY ANALYSES
We investigate the use of a different dataset for obtaining the genetic association estimates with CHD risk, and the impact of including different sets of genetic variants in the analyses. We also perform the Mendelian randomization analysis for Lp(a) separately in different study groupings according to the Lp(a) assay used in each study.
Two datasets are used to obtain genetic associations with CHD risk. These are the CHD Exome+ consortium (internal associations), and CARDIoGRAMplusC4D (2015 data release) (11) . We considered using CHD associations from the CARDIoGRAM 2011 data release and the CARDIoGRAMplusC4D 2013 data release; however, few associations were available for the genetic variants included in the LPA genetic score. The associations of the variants with CHD in the CARDIoGRAMplusC4D consortium were referenced using PhenoScanner (12) .
The CARDIoGRAMplusC4D (2015) estimates were obtained in up to 60,801 CAD cases and 123,504 controls, mostly of European descent with some South Asians and East Asians. These estimates are available for over 9 million variants. For each dataset, we used as many of the 43 variants from the LPA genetic score as were present in the target dataset. In total, 29 of the 43 variants in the LPA score were available in the CARDIoGRAMplusC4D dataset.
We also varied the number of genetic variants included in the analysis for the effect of Lp(a) on CHD risk. In Supplementary Table S4 , we show estimates using each of the CHD association datasets listed above for all 43 variants, also for the top 30 variants (the first 30 chosen by the stepwise selection algorithm), top 20, top 10, top 5, and for the 2 variants (rs10455872 and rs3798220) that were analysed by Clarke et al in their previous Mendelian randomization investigation (13) . Analyses using CARDIoGRAMplusC4D included all variants for which an association with CHD risk was available: We see that estimates were similar between the two datasets. Using fewer variants in the analysis led to slightly increased estimates, and more optimistic estimates for the effect of Lp(a) lowering on CHD risk than the primary analyses of this paper. This trend is somewhat expected; using more variants leads to more precise estimates, but can reduce the strength of instruments and hence increase the magnitude of weak instrument bias. In a two sample setting, this bias is towards the null -as observed here. (Although estimates were obtained in the same studies, the use of healthy participants only for associations with the exposure means that bias operates more similarly to a two sample setting.) However, discrepancies between estimates using different numbers of genetic variants were small.
Mendelian randomization estimates for CHD risk per 10 mg/dL lowering were similar across the three study groupings considered here (Copenhagen studies, EPIC CVD, and WOSCOPS, Supplementary Figure S7 ). This is despite baseline concentrations of Lp(a) differing markedly between the studies. As previously noted with the associations of the individual variants in Supplementary Figure S6 , this suggests that assay type affects the absolute concentration of Lp(a) reported, but it does not affect changes in Lp(a) concentration.
COMPARISON OF OBSERVATIONAL AND MENDELIAN RANDOMIZATION ESTIMATES
To calculate the predicted short term effect of Lp(a) lowering on CHD risk, we first calculate the ratio of the Mendelian randomization estimates for Lp(a) and LDL C, and then scale the short term effect of LDL C lowering taken from statin trials according to this ratio. To provide additional evidence that this approach is reasonable, we consider the ratio between the epidemiologic estimates for Lp(a) and LDL C, and compare this to the ratio of the Mendelian randomization estimates. In both cases, we use published data from the Emerging Risk Factors Collaboration (ERFC) to obtain the epidemiologic estimates.
For Lp(a), the ERFC published estimates of the association with CHD risk per 1 standard deviation increase (approximately 3.5 fold increase) in log transformed Lp(a), and for the upper tertile versus lower tertile of the Lp(a) distribution (3) . Neither of these estimates is particularly useful in calculating the association with CHD for absolute changes in Lp(a). We therefore took the values of Lp(a) and CHD risk in the deciles of the distribution of Lp(a) from Figure 2A (left panel) of the ERFC publication, and plotted these on a graph changing the horizontal axis from a log scale to an absolute scale (Supplementary Figure S9) . Associations with disease are for the outcome "non fatal myocardial infarction and coronary death", and the associations are adjusted for age and sex only. As can be seen from the graph (Supplementary Figure S9) , the epidemiologic association is compatible with a linear relationship between log transformed CHD risk and absolute changes in Lp(a). We then regressed the log risk of CHD in each decile against the level of Lp(a) with the intercept fixed at zero, and obtained an estimate of the log odds ratio of CHD risk per 10 mg/dL change in Lp(a). To account for regression dilution bias, we divided by 0.87 (the regression dilution ratio for Lp [a] reported in the same paper). We compared this to the estimate provided by the ERFC for usual levels of non HDL cholesterol adjusted for age and sex only, and with non fatal myocardial infarction and coronary death (14) . This estimate was already corrected for regression dilution bias.
It is important to note that although the ERFC reported the association between non HDL C concentration and risk of CHD in the primary analysis, all studies included in this meta analysis measured total cholesterol, high density lipoprotein cholesterol (HDL C) and triglycerides; and reported the calculated LDL C concentration as estimated by the Friedewald equation. The authors point out that any regression model that includes terms for non HDL C, HDL C and triglycerides is a simple mathematical rearrangement of a model that includes terms for calculated LDL C, HDL C and triglycerides. Therefore, in the ERFC analysis, the effect of LDL C is exactly equal to the effect of non HDL C on the risk of CHD by definition in the analysis. The authors confirmed this fact by demonstrating that in a sub sample of 8 studies involving 44,234 individuals, the effect of directly measured LDL C on the risk of CHD was nearly identical to the effect of non HDL C (and calculated LDL C) per mmol/L.
The observational association with CHD risk per 10 mg/dL increase in Lp(a) was a log odds ratio of 0.0383. The observational association with CHD risk per 43 mg/dL increase in non HDL C ( a 1 standard deviation change) was an odds ratio of 1.63. This translates to a log odds ratio of 0.1136 per 10 mg/dL increase in LDL C, meaning that the ratio between the epidemiologic observational associations is 2.96. In contrast, the ratio of the Mendelian randomization estimates was 2.63 (=0.1567/0.0597). The similarity of these two ratios (12% difference) gives additional confidence in the assumptions relating to the estimate of short term lowering of Lp(a). Per allele association estimates for 43 genetic variants included in the LPA score, and 2 variants previously used in Mendelian randomization investigation (Clarke et al) . Variants are listed in their order of inclusion in the genetic score from the stepwise selection algorithm. Mendelian randomization odds ratio estimate (95% confidence interval) for coronary heart disease (CHD) risk per 10 mg/dL lowering in lipoprotein(a) [Lp(a)] using six different choices of genetic score and two different datasets for obtaining genetic associations with CHD risk. 1 First 30 variants included in the genetic score from the stepwise selection algorithm. 2 These are the 2 variants (rs10455872 and rs3798220) that were analysed by Clarke et al in their
previous Mendelian randomization investigation (13) .
